Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

John Imig to Blood Pressure

This is a "connection" page, showing publications John Imig has written about Blood Pressure.

 
Connection Strength
  
 
 
4.716
  
  1. Imig JD, Hye Khan MA, Sharma A, Fish BL, Mandel NS, Cohen EP. Radiation-induced afferent arteriolar endothelial-dependent dysfunction involves decreased epoxygenase metabolites. Am J Physiol Heart Circ Physiol. 2016 06 01; 310(11):H1695-701.
    View in: PubMed
    Score: 0.445
  2. Hye Khan MA, Pavlov TS, Christain SV, Neck?r J, Staruschenko A, Gauthier KM, Capdevila JH, Falck JR, Campbell WB, Imig JD. Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clin Sci (Lond). 2014 Oct; 127(7):463-74.
    View in: PubMed
    Score: 0.399
  3. Hye Khan MA, Neck?r J, Manthati V, Errabelli R, Pavlov TS, Staruschenko A, Falck JR, Imig JD. Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat. Hypertension. 2013 Nov; 62(5):905-13.
    View in: PubMed
    Score: 0.370
  4. Imig JD. Adenosine2A receptors and epoxyeicosatrienoic acids: a recipe for salt and blood pressure regulation. Hypertension. 2009 Dec; 54(6):1223-5.
    View in: PubMed
    Score: 0.283
  5. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005 Oct; 46(4):975-81.
    View in: PubMed
    Score: 0.213
  6. Imig JD. 20-HETE or EETs: which arachidonic acid metabolite regulates proximal tubule transporters and contributes to pressure natriuresis? Am J Physiol Regul Integr Comp Physiol. 2004 Jul; 287(1):R3-5.
    View in: PubMed
    Score: 0.196
  7. Inscho EW, Cook AK, Murzynowski JB, Imig JD. Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation. J Hypertens. 2004 Apr; 22(4):811-8.
    View in: PubMed
    Score: 0.193
  8. Gawrys O, Huskov? Z, Baranowska I, Walkowska A, Sadowski J, Kikerlov? S, Vanourkov? Z, Honetschl?gerov? Z, ?karoupkov? P, Cervenka L, Falck JR, Imig JD, Kompanowska-Jezierska E. Combined treatment with epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid antagonist provides substantial hypotensive effect in spontaneously hypertensive rats. J Hypertens. 2020 09; 38(9):1802-1810.
    View in: PubMed
    Score: 0.150
  9. Neck?r J, Hye Khan MA, Gross GJ, Cyprov? M, Hrdlicka J, Kvasilov? A, Falck JR, Campbell WB, Sedl?kov? L, ?kutov? ?, Olejn?ckov? V, Gregorovicov? M, Sedmera D, Kol?r F, Imig JD. Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. Clin Sci (Lond). 2019 04 30; 133(8):939-951.
    View in: PubMed
    Score: 0.137
  10. Cervenka L, Huskov? Z, Kopkan L, Kikerlov? S, Sedl?kov? L, Vanourkov? Z, Al?nov? P, Kol?r F, Hammock BD, Hwang SH, Imig JD, Falck JR, Sadowski J, Kompanowska-Jezierska E, Neck?r J. Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension. J Hypertens. 2018 06; 36(6):1326-1341.
    View in: PubMed
    Score: 0.129
  11. Campbell WB, Imig JD, Schmitz JM, Falck JR. Orally Active Epoxyeicosatrienoic Acid Analogs. J Cardiovasc Pharmacol. 2017 Oct; 70(4):211-224.
    View in: PubMed
    Score: 0.123
  12. J?chov? ?, Kopkan L, Huskov? Z, Dole?elov? ?, Neck?r J, Kujal P, Vernerov? Z, Kramer HJ, Sadowski J, Kompanowska-Jezierska E, Reddy RN, Falck JR, Imig JD, Cervenka L. Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2016 10; 34(10):2008-25.
    View in: PubMed
    Score: 0.115
  13. Imig JD. Renal blood flow autoregulation: what are the contributions for nitric oxide or superoxide to modulate the myogenic response? Am J Physiol Renal Physiol. 2016 05 15; 310(10):F1013-5.
    View in: PubMed
    Score: 0.110
  14. Al?nov? P, Huskov? Z, Kopkan L, Sporkov? A, J?chov? ?, Neck?r J, Imig JD, Klevstig M, Kol?r F, Rami Reddy N, Falck JR, Sadowski J, Nishiyama A, Kramer HJ, Melenovsk? V, Cervenkov? L, Kujal P, Vernerov? Z, Cervenka L. Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. Vascul Pharmacol. 2015 Oct; 73:45-56.
    View in: PubMed
    Score: 0.106
  15. Hye Khan MA, Neck?r J, Haines J, Imig JD. Azilsartan improves glycemic status and reduces kidney damage in zucker diabetic fatty rats. Am J Hypertens. 2014 Aug; 27(8):1087-95.
    View in: PubMed
    Score: 0.096
  16. Capdevila JH, Pidkovka N, Mei S, Gong Y, Falck JR, Imig JD, Harris RC, Wang W. The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt. J Biol Chem. 2014 Feb 14; 289(7):4377-86.
    View in: PubMed
    Score: 0.095
  17. Imig JD, Walsh KA, Hye Khan MA, Nagasawa T, Cherian-Shaw M, Shaw SM, Hammock BD. Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor ? agonist improve vascular function and decrease renal injury in hypertensive obese rats. Exp Biol Med (Maywood). 2012 Dec; 237(12):1402-12.
    View in: PubMed
    Score: 0.088
  18. Honetschl?gerov? Z, Sporkov? A, Kopkan L, Huskov? Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerov? Z, Ch?bov? VC, Tesar V, Cervenka L. Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2011 Aug; 29(8):1590-601.
    View in: PubMed
    Score: 0.080
  19. Khan AH, Imig JD. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. Am J Hypertens. 2011 Jul; 24(7):816-21.
    View in: PubMed
    Score: 0.078
  20. Sporkov? A, Kopkan L, Varcabov? S, Huskov? Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Cervenka L. Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2011 Jun; 300(6):R1468-75.
    View in: PubMed
    Score: 0.078
  21. Honetschl?gerov? Z, Huskov? Z, Vanourkov? Z, Sporkov? A, Kramer HJ, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Cervenka L, Kopkan L. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J Physiol. 2011 Jan 01; 589(Pt 1):207-19.
    View in: PubMed
    Score: 0.077
  22. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow AL, Lepp AN, Kannon MA, Ronnekleiv OK, Alkayed NJ, Falck JR, Tomer KB, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 2010 Oct; 24(10):3770-81.
    View in: PubMed
    Score: 0.074
  23. Elmarakby AA, Imig JD. Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. Clin Sci (Lond). 2010 Feb; 118(4):291-301.
    View in: PubMed
    Score: 0.072
  24. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol. 2009 Sep; 297(3):F740-8.
    View in: PubMed
    Score: 0.069
  25. Quigley JE, Elmarakby AA, Knight SF, Manhiani MM, Stepp DW, Olearzcyk JJ, Imig JD. Obesity induced renal oxidative stress contributes to renal injury in salt-sensitive hypertension. Clin Exp Pharmacol Physiol. 2009 Jul; 36(7):724-8.
    View in: PubMed
    Score: 0.067
  26. Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, Couse JF, Quigley R, Harder DR, Zhao X, Imig JD, Pedersen TL, Newman JW, Hammock BD, Conley AJ, Korach KS, Coffman TM, Zeldin DC. Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J. 2008 Dec; 22(12):4096-108.
    View in: PubMed
    Score: 0.065
  27. Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD. Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension. 2008 Feb; 51(2):352-9.
    View in: PubMed
    Score: 0.062
  28. Elmarakby AA, Quigley JE, Pollock DM, Imig JD. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension. 2006 Mar; 47(3):557-62.
    View in: PubMed
    Score: 0.055
  29. Lee DL, Sturgis LC, Labazi H, Osborne JB, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol. 2006 Mar; 290(3):H935-40.
    View in: PubMed
    Score: 0.054
  30. Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM. Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension. 2005 Aug; 46(2):366-71.
    View in: PubMed
    Score: 0.052
  31. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 2004 May; 15(5):1244-53.
    View in: PubMed
    Score: 0.048
  32. Zhao X, Pollock DM, Zeldin DC, Imig JD. Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. Hypertension. 2003 Oct; 42(4):775-80.
    View in: PubMed
    Score: 0.046
  33. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002 Feb; 39(2 Pt 2):690-4.
    View in: PubMed
    Score: 0.041
  34. Klemens CA, Chulkov EG, Wu J, Hye Khan MA, Levchenko V, Flister MJ, Imig JD, Kriegel AJ, Palygin O, Staruschenko A. Loss of Chloride Channel 6 (CLC-6) Affects Vascular Smooth Muscle Contractility and Arterial Stiffness via Alterations to Golgi Calcium Stores. Hypertension. 2021 02; 77(2):582-593.
    View in: PubMed
    Score: 0.038
  35. Miller B, Palygin O, Rufanova VA, Chong A, Lazar J, Jacob HJ, Mattson D, Roman RJ, Williams JM, Cowley AW, Geurts AM, Staruschenko A, Imig JD, Sorokin A. p66Shc regulates renal vascular tone in hypertension-induced nephropathy. J Clin Invest. 2016 07 01; 126(7):2533-46.
    View in: PubMed
    Score: 0.028
  36. Hye Khan MA, Fish B, Wahl G, Sharma A, Falck JR, Paudyal MP, Moulder JE, Imig JD, Cohen EP. Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy. Clin Sci (Lond). 2016 Apr; 130(8):587-99.
    View in: PubMed
    Score: 0.027
  37. Nayak S, Khan MA, Wan TC, Pei H, Linden J, Dwinell MR, Geurts AM, Imig JD, Auchampach JA. Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension. Purinergic Signal. 2015 Dec; 11(4):519-31.
    View in: PubMed
    Score: 0.027
  38. Sporkov? A, J?chov? S, Huskov? Z, Kopkan L, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Cervenka L. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol. 2014 Dec; 41(12):1003-13.
    View in: PubMed
    Score: 0.025
  39. Kim J, Yoon SP, Toews ML, Imig JD, Hwang SH, Hammock BD, Padanilam BJ. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. Am J Physiol Renal Physiol. 2015 Jan 15; 308(2):F131-9.
    View in: PubMed
    Score: 0.025
  40. Kujal P, Cert?kov? Ch?bov? V, ?karoupkov? P, Huskov? Z, Vernerov? Z, Kramer HJ, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kitada K, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Cervenka L. Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. Clin Exp Pharmacol Physiol. 2014 Mar; 41(3):227-37.
    View in: PubMed
    Score: 0.024
  41. Varcabova S, Huskova Z, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Kitada K, Cervenka L. Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system. Clin Exp Pharmacol Physiol. 2013 Apr; 40(4):273-81.
    View in: PubMed
    Score: 0.022
  42. Honetschl?gerov? Z, Kitada K, Huskov? Z, Sporkov? A, Kopkan L, B?rgelov? M, Varcabov? ?, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerov? Z, Cervenka L. Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. J Hypertens. 2013 Feb; 31(2):321-32.
    View in: PubMed
    Score: 0.022
  43. Neck?r J, Kopkan L, Huskov? Z, Kol?r F, Papou?ek F, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Mal? J, Netuka I, O?t?dal B, Cervenka L. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin Sci (Lond). 2012 Jun; 122(11):513-25.
    View in: PubMed
    Score: 0.021
  44. Cert?kov? Ch?bov? V, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerov? Z, Vanourkov? Z, Kopkan L, Kramer HJ, Falck JR, Imig JD, Hammock BD, Vaneckov? I, Cervenka L. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci (Lond). 2010 Feb 23; 118(10):617-32.
    View in: PubMed
    Score: 0.018
  45. Quigley R, Chakravarty S, Zhao X, Imig JD, Capdevila JH. Increased renal proximal convoluted tubule transport contributes to hypertension in Cyp4a14 knockout mice. Nephron Physiol. 2009; 113(4):p23-8.
    View in: PubMed
    Score: 0.018
  46. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM. TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2008 Jan; 294(1):R76-83.
    View in: PubMed
    Score: 0.015
  47. Guan Y, Zhang Y, Wu J, Qi Z, Yang G, Dou D, Gao Y, Chen L, Zhang X, Davis LS, Wei M, Fan X, Carmosino M, Hao C, Imig JD, Breyer RM, Breyer MD. Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest. 2007 Sep; 117(9):2496-505.
    View in: PubMed
    Score: 0.015
  48. Cert?kov? Ch?bov? V, Kramer HJ, Vaneckov? I, Thumov? M, Skaroupkov? P, Tesar V, Falck JR, Imig JD, Cervenka L. The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. Kidney Blood Press Res. 2007; 30(5):335-46.
    View in: PubMed
    Score: 0.015
  49. Socha MJ, Manhiani M, Said N, Imig JD, Motamed K. Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. Am J Pathol. 2007 Oct; 171(4):1104-12.
    View in: PubMed
    Score: 0.015
  50. Ch?bov? VC, Kramer HJ, Vaneckov? I, Vernerov? Z, Eis V, Tesar V, Skaroupkov? P, Thumov? M, Schejbalov? S, Huskov? Z, Vanourkov? Z, Kolsk? A, Imig JD, Cervenka L. Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol. 2007 Aug-Sep; 47(2-3):145-59.
    View in: PubMed
    Score: 0.015
  51. Kang KT, Sullivan JC, Sasser JM, Imig JD, Pollock JS. Novel nitric oxide synthase--dependent mechanism of vasorelaxation in small arteries from hypertensive rats. Hypertension. 2007 Apr; 49(4):893-901.
    View in: PubMed
    Score: 0.015
  52. Elmarakby AA, Williams JM, Imig JD, Pollock JS, Pollock DM. Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension. Vascul Pharmacol. 2007 Feb; 46(2):144-51.
    View in: PubMed
    Score: 0.014
  53. Zhao X, Cook AK, Field M, Edwards B, Zhang S, Zhang Z, Pollock JS, Imig JD, Inscho EW. Impaired Ca2+ signaling attenuates P2X receptor-mediated vasoconstriction of afferent arterioles in angiotensin II hypertension. Hypertension. 2005 Sep; 46(3):562-8.
    View in: PubMed
    Score: 0.013
  54. Pollock DM, Jenkins JM, Cook AK, Imig JD, Inscho EW. L-type calcium channels in the renal microcirculatory response to endothelin. Am J Physiol Renal Physiol. 2005 Apr; 288(4):F771-7.
    View in: PubMed
    Score: 0.013
  55. Wang MH, Smith A, Zhou Y, Chang HH, Lin S, Zhao X, Imig JD, Dorrance AM. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension. 2003 Oct; 42(4):594-9.
    View in: PubMed
    Score: 0.012
  56. Zhuo JL, Imig JD, Hammond TG, Orengo S, Benes E, Navar LG. Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. Hypertension. 2002 Jan; 39(1):116-21.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.